AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Seres Therapeutics to Present at the Cowen 2020 Health Care Conference

February 25, 2020 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 25, 2020--

Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma. SER-301, a next-generation, rationally-designed, live microbiome therapeutic candidate is in preclinical development for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200225005233/en/

CONTACT: Carlo Tanzi, Ph.D., 617-203-3467

ctanzi@serestherapeutics.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Seres Therapeutics

Copyright Business Wire 2020.

PUB: 02/25/2020 04:00 PM/DISC: 02/25/2020 04:00 PM

http://www.businesswire.com/news/home/20200225005233/en